A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

This study has been withdrawn prior to enrollment.
(Study closed by Protocol Review Monitoring Committee because of lack of accrual)
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
University of Kansas
ClinicalTrials.gov Identifier:
NCT01163929
First received: July 14, 2010
Last updated: October 22, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: March 2012
  Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)